A real‐world study to assess the association of cardiovascular adverse events (CVAEs) with ibrutinib as first‐line (1L) treatment for patients with chronic lymphocytic leukaemia (CLL) in the United States

Ibrutinib, a Bruton's tyrosine kinase inhibitor, is often used as first‐line (1L) treatment of chronic lymphocytic leukaemia (CLL); however, it is associated with an increased risk for cardiovascular adverse events (CVAEs). This real‐world study adds to existing literature by simultaneously inv...

Descripción completa

Detalles Bibliográficos
Autores principales: Mato, Anthony, Tang, Boxiong, Azmi, Soraya, Yang, Keri, Han, Yi, Zhang, Xiaowei, Roeker, Lindsey, Wallis, Nicola, Stern, Jennifer C., Hedrick, Eric, Huang, Jane, Sharman, Jeff P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Haematologic Malignancy ‐ Lymphoid
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9928661/
https://www.ncbi.nlm.nih.gov/pubmed/36819172
http://dx.doi.org/10.1002/jha2.638

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9928661/
https://www.ncbi.nlm.nih.gov/pubmed/36819172
http://dx.doi.org/10.1002/jha2.638

Ejemplares similares